My Amyotrophic Lateral Sclerosis (ALS) Journey from Weakness to Diagnosis: A Journey of Hope

TL;DR

This paper shares the personal journey of an ALS patient and highlights the need for better genetic analysis, inclusive clinical trials, and collaborative drug development.

Contribution

The paper emphasizes the importance of patient involvement and broader collaboration in ALS research and treatment development.

Findings

Genetic analysis should be recommended early in ALS diagnosis to include patients in clinical trials.

Collaboration among patients, scientists, and clinicians is essential for developing effective ALS therapies.

ALS patients play a crucial role in raising awareness and driving research efforts.

Abstract

Genetic analysis is still a challenge in ALS. It should be recommended during diagnosis, leading to early inclusion of patients in the clinical trials.

Eligibility criteria in ALS clinical trials are strict. Refining inclusion criteria, including patients from all clinical stages of progression, is needed.

Canadian health care providers provide meaningful support to ALS patients.

The drug discovery and development pipeline for creating effective ALS therapies should involve a wider collaborative community, including patients, caregivers, basic scientists, clinicians, and medicinal chemists.

Funding research is just as crucial as funding healthcare by the government. Innovations from laboratories turn into real health solutions. Therefore, supporting research in ALS is essential.

Genetic analysis is still a challenge in ALS. It should be recommended during diagnosis, leading to early inclusion of patients in the clinical trials.

Eligibility criteria in ALS clinical trials are strict. Refining inclusion criteria, including patients from all clinical stages of progression, is needed.

Canadian health care providers provide meaningful support to ALS patients.

The drug discovery and development pipeline for creating effective ALS therapies should involve a wider collaborative community, including patients, caregivers, basic scientists, clinicians, and medicinal chemists.

Funding research is just as crucial as funding healthcare by the government. Innovations from laboratories turn into real health solutions. Therefore, supporting research in ALS is essential.

Amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease is a progressive neurodegenerative disease that attacks and kills motor neurons in the brain and spinal cord, leading to muscle weakness and atrophy, eventually causing respiratory failure and death within 2–5 years after diagnosis. By 2040, the global population of individuals living with ALS is projected to approach 400,000. Since ALS was discovered by Charcot 150 years ago, only two drugs (Edaravone and Riluzole) have been available, offering modest clinical benefits in slowing disease progression. The increasing number of cases, along with the high costs of treatment and care, creates a growing burden on communities and the healthcare system. However, despite this rising burden and the failure of most clinical trials, the ALS community remains hopeful because of the patients themselves. ALS patients are the beating heart of the ALS community. They engage in efforts to improve lives for others, raising awareness through their real-life experiences, participating in research activities, fundraising, providing samples for research, and advocating strongly in front of communities and governments to raise funds. Their engagement is highly valuable, and collaboration with the research community is essential to understanding the disease process and developing effective disease-modifying therapies. Here, we share the story of Mrs. Sherry Wityshyn, an ALS patient and a true ALS warrior from Winnipeg, Manitoba, Canada. We believe her story will inspire and motivate the entire community to learn more about ALS. Furthermore, her story gives hope to everyone impacted. In this manuscript, we also emphasize the different stages of Sherry’s journey from weakness to diagnosis and our efforts to share her enduring words with policymakers in the government.

Figures